Patency Trials With Reteplase (r-PA): What Do They Tell Us?

This publication has 20 references indexed in Scilit:

• More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction
  Circulation, 1995
• Dose finding with a novel recombinant plasminogen activator (BM 06,022) in patients with acute myocardial infarction: Results of the German recombinant plasminogen activator study
  Journal of the American College of Cardiology, 1994
• The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction
  The American Journal of Cardiology, 1993
• Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro
  Blood Coagulation & Fibrinolysis, 1993
• Rapid Reversal of Canine Thromboembolic Pulmonary Hypertension by Bolus Injection of the Novel Recombinant Plasminogen Activator BM 06.022
  Journal of Cardiovascular Pharmacology, 1993
• Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis
  Journal of the American College of Cardiology, 1992
• Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates
  Fibrinolysis, 1992
• Serpin-resistant mutants of human tissue-type plasminogen activator
  Nature, 1989